Table 2 Treatment outcome of cases treated with either artemether–lumefantrine or dihydroartemisinin at Muheza and Ujiji
Outcome | Muheza—AL (n = 96) | Ujiji—AL (N = 161) | ||||||
|---|---|---|---|---|---|---|---|---|
Day 28 follow-up | Day 42 follow-up | Day 28 follow-up | Day 42 follow-up | |||||
PCR uncorrected | PCR corrected | PCR uncorrected | PCR corrected | PCR uncorrected | PCR corrected | PCR uncorrected | PCR corrected | |
ETF | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
LCF | 11 (12.0) | 0 (0.0) | 19 (21.6) | 0 (0.0) | 15 (9.6) | 3 (2.6) | 23 (15.1) | 3 (4.1) |
LPF | 10 (10.9) | 0 (0.0) | 16 (18.2) | 0 (0.0) | 30 (19.2) | 0 (0.0) | 59 (38.8) | 1 (1.4) |
ACPR | 71 (77.2) | 71 (100.0) | 53 (60.2) | 53 (100.0) | 111 (71.2) | 111 (97.4) | 70 (46.1) | 70 (94.6) |
WTH/LFU | 4 (4.2) | 25 (26.0) | 8 (8.3) | 40 (43.0) | 5 (3.1) | 44 (27.8) | 9 (5.6) | 82 (52.6) |
PCR ND | NA | 0 | NA | 3 (3.1) | NA | 3 (1.9) | NA | 5 (3.1) |
Outcome | MUHEZA—DP (96) | UJIJI—DP (N = 156) | ||||||
|---|---|---|---|---|---|---|---|---|
Day 42 follow-up | Day 63 follow-up | Day 42 follow-up | Day 63 follow-up | |||||
PCR uncorrected | PCR corrected | PCR uncorrected | PCR corrected | PCR uncorrected | PCR corrected | PCR uncorrected | PCR corrected | |
ETF | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
LCF | 4 (4.6) | 0 (0.0) | 17 (20.0) | 0 (0.0) | 11 (7.4) | 1 (0.9) | 31 (21.5)) | 1 (1.6) |
LPF | 19 (21.8) | 2 (3.0) | 19 (22.4) | 3 (5.8) | 30 (20.1) | 0 (0.0) | 55 (38.2) | 2 (3.3) |
ACPR | 64 (73.6) | 64 (97.0) | 49 (57.6) | 49 (94.2) | 108 (72.5) | 108 (99.1) | 58 (40.3) | 58 (95.1) |
WTH/LFU | 9 (9.4) | 25 (27.5) | 11 (11.5) | 38 (42.2) | 7 (4.5) | 46 (29.7) | 12 (7.7) | 90 (59.6) |
PCR ND | NA | 5 (5.2) | NA | 6 (6.3) | NA | 1 (0.6) | NA | 5 (3.2) |